Factors affecting mortality in COVID-19-associated pulmonary aspergillosis: An international ID-IRI study

Basit Öğe Kaydı
dc.authoridEmecen, Ahmet Naci/0000-0003-3995-0591
dc.authoridRashid, Naveed/0009-0002-9549-1289
dc.authoridErdem, Hakan/0000-0002-6265-5227
dc.authoridUnver Ulusoy, Tulay/0000-0002-0172-2326
dc.authoridHakamifard, Atousa/0000-0001-9456-2239
dc.authoridSahin, Meyha/0000-0003-4147-3587
dc.contributor.authorSahin, Meyha
dc.contributor.authorYilmaz, Mesut
dc.contributor.authorMert, Ali
dc.contributor.authorEmecen, Ahmet Naci
dc.contributor.authorAl Maslamani, Muna A. Rahman S.
dc.contributor.authorHashim, Samar Mahmoud A.
dc.contributor.authorIttaman, Ajithkumar Valooparambil
dc.date.accessioned2025-01-27T20:29:08Z
dc.date.available2025-01-27T20:29:08Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground: This study aimed to identify factors that influence the mortality rate of patients with coronavirus disease (COVID-19)-associated pulmonary aspergillosis (CAPA). Methods: In this cross-sectional study, data from 23 centers across 15 countries, spanning the period of March 2020 to December 2021, were retrospectively collected. The study population comprised patients who developed invasive pulmonary aspergillosis while being treated for COVID-19 in the intensive care unit. Cox regression and decision tree analyses were used to identify factors associated with mortality in patients with CAPA. Results: A total of 162 patients (males, 65.4 %; median age: 64 [25th-75th: 54.0-73.8] years) were included in the study, of whom 113 died during the 90-day follow-up period. The median duration from CAPA diagnosis to death was 12 (25th-75th: 7-19) days. In the multivariable Cox regression model, an age of >= 65 years (hazard ratio [HR]: 2.05, 95 % confidence interval [CI]: 1.37-3.07), requiring vasopressor therapy at the time of CAPA diagnosis (HR: 1.80, 95 % CI: 1.17-2.76), and receiving renal replacement therapy at the time of CAPA diagnosis (HR: 2.27, 95 % CI: 1.35-3.82) were identified as predictors of mortality. Decision tree analysis revealed that patients with CAPA aged >= 65 years who received corticosteroid treatment for COVID-19 displayed higher mortality rates (estimated rate: 1.6, observed in 46 % of patients). Conclusion: This study concluded that elderly patients with CAPA who receive corticosteroids are at a significantly higher risk of mortality, particularly if they experience multiorgan failure.
dc.description.sponsorshipThis study was conducted in accordance with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Istanbul Medipol University (number and date of ethical approval: E-10840098-772.02-1631 and March 05, 2022, respectively) .
dc.identifier.doi10.1016/j.heliyon.2024.e34325
dc.identifier.issn2405-8440
dc.identifier.issue14
dc.identifier.pmid39082033
dc.identifier.scopus2-s2.0-85198244806
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.heliyon.2024.e34325
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22840
dc.identifier.volume10
dc.identifier.wosWOS:001272308400001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherCell Press
dc.relation.ispartofHeliyon
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectCOVID-19
dc.subjectCOVID-19-associated aspergillosis
dc.subjectIntensive care unit
dc.subjectMortality
dc.titleFactors affecting mortality in COVID-19-associated pulmonary aspergillosis: An international ID-IRI study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu